MedTrace Logo

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

NCT00236379 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2011-05-17

No results posted yet for this study

Summary

The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.

Conditions

Interventions

DRUG

Olanzapine

Target oral dose of 20 milligrams per day for 6 months

DRUG

Risperidone

Target oral dose of 6 milligrams per day for for 6 months

Sponsors & Collaborators

  • Janssen, LP

    lead INDUSTRY

Principal Investigators

  • Janssen, LP Clinical Trial · Janssen, LP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2003-08-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00236379 on ClinicalTrials.gov